1. Factors associated with virological response to etravirine in non

1.
Factors associated with virological response to etravirine in non nucleoside reverse
transcriptase inhibitor experienced HIV-1 infected patients.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA,
Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G,
Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez
V; the ANRS AC11 Resistance study group.
Antimicrob Agents Chemother. 2009 Nov 9.
2.
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir
among treatment-experienced patients infected with multidrug-resistant HIV: results of the
ANRS 139 TRIO trial.
Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G,
Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.
Clin Infect Dis. 2009 Nov 1;49(9):1441-9
3. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after longterm suppressive antiretroviral therapy in 236 patients.
Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P,
Seigneurin JM, Rouzioux C; ANRS AC11 Working Group.
AIDS. 2009 Oct 23;23(16):2165-71
4 Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive
HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M,
Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.
J Antimicrob Chemother. 2009 Jul;64(1):118-25.
5 Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive
HIV-2-infected patients.
Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F,
Autran B, Brun-Vézinet F, Chêne G, Matheron S; ANRS CO5 HIV-2 Cohort Study Group.
AIDS. 2009 Jun 1;23(9):1171-3.
6 Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drugexperienced patients besides compensating for fitness loss.
Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F;
ANRS 109 Study Group.
PLoS Pathog. 2009 Mar;5(3):e1000345. .
8 The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1
ubiquitin ligase to overcome a postentry block in macrophage infection.
Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, BrunVezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C.
J Virol. 2009 May;83(10):4854-60.
9 Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected
protease inhibitor-experienced patients.
Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M,
Calvez V, Brun-Vézinet F.
J Antimicrob Chemother. 2009 Mar;63(3):585-92.
10 A new human immunodeficiency virus derived from gorillas.
Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL,
Simon F.
Nat Med. 2009 Aug;15(8):871-2.
11 Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S.
AIDS. 2009 Jan 28;23(3):426-8.
12 Development of a didanosine genotypic resistance interpretation system based on large
derivation and validation datasets.
Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V,
Flandre P, Costagliola D; on behalf of the Standardization, Clinical Relevance of HIV Drug Resistance
Testing Project from the Forum for Collaborative HIV Research.
AIDS. 2009 Oct 27.
13 Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients
depends on PI used in HAART regimen--ANRS 111 trial.
Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux
C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group.
Fundam Clin Pharmacol. 2009 Aug;23(4):491-500.
14 Factors associated with non-adherence to long-term highly active antiretroviral therapy: a
10 year follow-up analysis with correction for the bias induced by missing data.
Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS
CO8 APROCO-COPILOTE Study Group.
J Antimicrob Chemother. 2009 Sep;64(3):599-606
15 Predictive value of HIV-1 genotypic resistance test interpretation algorithms.
Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K,
Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW.
J Infect Dis. 2009 Aug 1;200(3):453-63.
16 Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIVinfected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study.
Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chêne G, Leport C,
Moing VL; ANRS CO8 (APROCO-COPILOTE) Study Group.
J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):407-15.
17 Influence of pharmacogenetics on indinavir disposition and short-term response in HIV
patients initiating HAART.
Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Céron D, Duval X, Mentré F;
COPHAR2-ANRS 111 Study Group.
Eur J Clin Pharmacol. 2009 Jul;65(7):667-78.
18 Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected
adults.
Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F; ANRS CO8
APROCO-COPILOTE study group.
AIDS. 2009 May 15;23(8):1021-4
19 Costs and cost-effectiveness of different follow-up schedules for detection of occupational
hepatitis C virus infection.
Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y.
Gut. 2009 Jan;58(1):105-10.
20 Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in
the POWER 1, 2 and 3 trials at week 96.
Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S,
Vangeneugden T, Tomaka F.
Antivir Ther. 2009;14(6):859-64.
21, Cerebral microbleeds are frequent in infective endocarditis: a case-control study.
Klein I, Iung B, Labreuche J, Hess A, Wolff M, Messika-Zeitoun D, Lavallée P, Laissy JP, Leport C,
Duval X; IMAGE Study Group.
Stroke. 2009 Nov;40(11):3461-5.
22 Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week
analysis of two randomized, controlled trials.
Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M,
Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups.
AIDS. 2009 Nov 13;23(17):2289-300.
23 Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who
have previously failed antiretroviral therapy.
Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M,
Woodfall B.
Antivir Ther. 2009;14(5):713-22.
24 Activation and coagulation biomarkers are independent predictors of the development of
opportunistic disease in patients with HIV infection.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN;
INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
J Infect Dis. 2009 Sep 15;200(6):973-83
25 Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell
counts < 350 cells/microl.
Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S;
FHDH-ANRS CO4 Clinical Epidemiology Group.
AIDS. 2009 Sep 24;23(15):1997-2004.
26 Systematic evaluation and description of anal pathology in HIV-infected patients during the
HAART era.
Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X.
Dis Colon Rectum. 2009 Jun;52(6):1130-6
27 Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary
infection over 1996-2006 in France.
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J,
Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO
ANRS CO 6; FHDH ANRS CO4 Study Groups.
AIDS. 2009 Mar 27;23(6):717-24.
28 Variable impact on mortality of AIDS-defining events diagnosed during combination
antiretroviral therapy: not all AIDS-defining conditions are created equal.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar
S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet
F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51
29 Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P,
Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales
EN19 Mortalité Study Group; Mortavic Study Group.
Clin Infect Dis. 2009 Mar 1;48(5):633-9.
30 Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with
lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ,
Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team.
HIV Med. 2009 Feb;10(2):116-24.
31 How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of
the French hospital database on HIV, Mortalité 2000 survey and death certificates.
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D; Clinical
Epidemiologic Group of the French Hospital Database on HIV (ANRS CO4 FHDH); Groupe d'Etude
Mortalité 2000.
HIV Med. 2009 Apr;10(4):236-45.
32 Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in
HIV-infected patients: results from FHDH ANRS CO4.
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y,
Costagliola D; FHDH ANRS CO4 ANRS CO141.
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14.
33 Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker
H, Ross M; INSIGHT SMART Study Group.
AIDS. 2009 Jan 2;23(1):71-82.
34 Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease
inhibitors: a randomized trial.
Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F,
Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D.
AIDS. 2009 Oct 15.
35 Contribution and limit of the model of perfused cotyledon to the study of placental transfer
of drugs. Example of a protease inhibitor of HIV: nelfinavir.
Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S.
Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):157-60
36 Clinical and resistance consequences of misquantification of plasma and cerebrospinal
fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected
patient.
Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F.
J Clin Microbiol. 2009 Nov;47(11):3763-4
37 Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients
depends on PI used in HAART regimen--ANRS 111 trial.
Duval X, Mentré F, Rey E, Auleley S, Peytavin G, Biour M, Métro A, Goujard C, Taburet AM, Lascoux
C, Panhard X, Tréluyer JM, Salmon-Céron D; Cophar 2 Study Group.
Fundam Clin Pharmacol. 2009 Aug;23(4):491-500.
38 Absence of a relation between efavirenz plasma concentrations and toxicity-driven
efavirenz discontinuations in the EuroSIDA study.
van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna
A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group.
Antivir Ther. 2009;14(1):75-83
39 Clinical pharmacokinetic of maraviroc]
Peytavin G.
Med Mal Infect. 2008 Mar;38 Suppl 1:S12-6
40 High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine
combination in naive HIV-1-infected patients.
Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C,
Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
J Antimicrob Chemother. 2009 Feb;63(2):380-8
41 Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their
neonates (ANRS 12109).
Hirt D, Urien S, Ekouévi DK, Rey E, Arrivé E, Blanche S, Amani-Bosse C, Nerrienet E, Gray G, Kone
M, Leang SK, McIntyre J, Dabis F, Tréluyer JM; ANRS 12109.
Clin Pharmacol Ther. 2009 Feb;85(2):182-9.
42 Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.
Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, Schneider V, Burgard M,
Faye A, Mandelbrot L, Tubiana R, Rouzioux C; ANRS French Perinatal Cohort.
Retrovirology. 2009 Sep 19;6:85.
43 No relation between in-utero exposure to HAART and intrauterine growth retardation.
Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C,
Blanche S, Warszawski J; ANRS French Perinatal Cohort.
AIDS. 2009 Jun 19;23(10):1235-43.
44 Variable impact on mortality of AIDS-defining events diagnosed during combination
antiretroviral therapy: not all AIDS-defining conditions are created equal.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar
S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet
F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51
45 Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in
HIV-infected patients: results from FHDH ANRS CO4.
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y,
Costagliola D; FHDH ANRS CO4 ANRS CO141.
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):206-14.
46 Amniocentesis and mother-to-child human immunodeficiency virus transmission in the
Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort.
Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R,
Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (EPF).
Am J Obstet Gynecol. 2009 Feb;200(2):160.e1-9.
47 Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal: A 96-Week Pilot
Trial in Treatment-Naive Patients.
Landman R, Poupard M, Diallo M, Gueye NF, Diakhate N, Ndiaye B, Kane CT, Trylesinski A, Diop H,
Mboup S, Fall MB, Deleporte E, Benalycherif AD, Girard PM, Sow PS.
J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Sep 15
48 Simplification and first validation of a short battery of patient questionnaires for clinical
management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence)
Questionnaire.
Spire B, Arnould B, Barbier F, Durant J, Gilquin J, Landman R, Carret S, Saussier C, El Kebir S,
Cohen-Codar I.
HIV Clin Trials. 2009 Jul-Aug;10(4):215-32.
49 Activation and coagulation biomarkers are independent predictors of the development of
opportunistic disease in patients with HIV infection.
Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN;
INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
J Infect Dis. 2009 Sep 15;200(6):973-83.
50 HIV genetic diversity and its consequences.]
Roquebert B, Damond F, Brun-Vézinet F, Descamps D.
Pathol Biol (Paris). 2009 Mar;57(2):142-8.